MLV Pounds the Table on BioCryst Pharmaceuticals, Inc.
MLV analyst Vernon Bernardino was out pounding the table on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), reiterating a Buy rating and price target of $15, which represents a potential upside of 85% from where the stock is currently trading.
Bernardino wrote, "BioCryst made significant progress in 2014 with its oral drug development programs for rare diseases. The company’s 1st-gen oral kallikrein inhibitor (KI), BCX4161, appears on track for OPuS-2 to report results by YE15, and BCRX stands ready to advance BCX7353, its 2nd-gen oral KI drug for treating hereditary angioedema (HAE), into Ph 1 in 2Q15. With its greater oral bioavailability, we believe the latter holds additional promise vs. BCX4161 to improve outcomes in HAE patients."
Furthermore, "As BCRX is quietly executing on all fronts, including generating initial sales of its flu drug, Rapivab (peramivir) and the advancement of antiviral candidate BCX4430 for Ebola virus disease (EVD), which is externally funded with grants from the US National Institute of Allergy and Infectious Diseases (NIAID), we believe the shares, which are down 25% YTD, are at attractive prices."
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Vernon Bernardino has a total average return of -7.8% and a 31.0% success rate. Bernardino has a -17.7% average return when recommending BCRX, and is ranked #3403 out of 3546 analysts.